THE UNMET NEED
Around three million Americans have type 1 diabetes.1
The annual healthcare costs associated with type 1 diabetes are $14.9 billion in the USA alone.2
Up to 4.5% of the global population is diagnosed with an autoimmune disease.3
THE PIONEERING SOLUTION
Diavacs is a clinical stage biotechnology company developing a novel immunotherapy to re-induce tolerance in type 1 diabetes and a multitude of other autoimmune diseases.
DiaVacs’ treatment offers local antigen-specific immunosuppression, halting the pathogenic autoimmune response, without compromising the body’s immune system. It also complements emerging regenerative approaches by protecting newly created beta cells from autoimmune attack.
1. JDRF. Type 1 Diabetes. Facts 2011: http://www2.jdrf.org/site/DocServer/KW-T1D_Factsheet.pdf?docID=1024 Accessed April 2018. 2. Dall TM et al. Popul Health Manag 2009; 12(2): 103–110 3. Hayter SM and Cook MC. Autoimmune Rev 2012; 11(10): 754–765.